^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

RAPT THERAPEUTICS REPORTS POSITIVE INITIAL DATA FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF FLX475 IN MULTIPLE CANCER INDICATIONS

Published date:
11/16/2020
Excerpt:
Of the 10 evaluable patients with head and neck cancers treated with FLX475 monotherapy, five of 10 (5/10) patients exhibited stable disease as best response.
Trial ID: